查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1656922

粘膜药:市场洞察·竞争情形·市场预测 (～2032年)

Transmucosal Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

透粘膜药物市场规模预计将从 2024 年的 16,652,020 百万美元增长到 2032 年的 28,191,420 百万美元，预测期内的复合年增长率为 6.85%。

透皮药物的需求主要受心血管疾病等慢性疾病发生率上升的推动。透皮药物的采用率不断提高、研发活动的增加以及主要公司之间的合作是推动市场积极成长的一些因素。

透皮药物的市场动态：

慢性病盛行率的上升预计将推动市场成长。根据美国政府 2024 年 3 月提供的数据，截至 2023 年的财政年度，英国有超过 1,862,500 人被诊断出患有冠状动脉心臟病 (CHD)。舌下片是放置在舌下，在舌下可迅速溶解并直接被血液吸收。这种高效的药物吸收有利于心绞痛和冠心病患者的病情快速缓解。硝酸司他等药物含有硝酸甘油，用于缓解冠状动脉疾病患者的胸痛（心绞痛），冠状动脉疾病的特征是心臟血流量减少。因此，慢性病盛行率的上升预计将推动市场成长。

根据英国政府 2024 年 2 月的公告，2021 年至 2022 年期间，21.8% 的英国成年人口报告患有忧郁或焦虑症。在某些情况下，口服劳拉西泮可用于急性治疗焦虑和癫痫。这些製剂透过口腔黏膜迅速吸收，并立即起效。因此，神经系统疾病的增加预计将推动市场成长。

市场成长的动力来自于专注于开发先进医药产品的公司加强研发活动的力度。这些公司专注于开发能够快速起效的创新药膜，以增强透粘膜药物的功效。预计主要参与者的此类技术创新将推动市场扩张。

根据产品，平板电脑领域预计在 2024 年占据较大的收入占有率。这是因为颊含片和舌下含片有这些优点。主要优点是颊含片或舌下片中所含活性成分的作用迅速起效。这些药片可以放在舌下，能够快速被吸收并立即产生效果。此片剂的开发旨在减少首过代谢，提高药物的生物利用度，为胃肠道发炎患者提供便利。此类颊含片和舌下片的益处促进了该市场的成长。

按地区划分，预计北美将在 2024 年占据最大占有率。这主要是由于高血压和神经系统疾病等慢性病发生率上升，以及各大公司加强研发。

本报告提供全球粘膜药的市场调查，彙整市场概要，市场影响因素及市场机会分析，法律制度，市场规模的转变·预测，各种区分·地区/各主要国家的详细分析，竞争情形，主要企业简介等资讯。

目录

第1章 粘膜药市场报告:简介

  • 调查范围
  • 市场区隔
  • 市场前提条件

第2章 粘膜药市场:摘要整理

  • 市场概要

第3章 竞争情形

第4章 法规分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第5章 粘膜药市场:主要要素分析

  • 推动市场要素
    • 慢性病发生率上升
    • 越来越多采用透皮药物
    • 加强研发活动与主要公司之间的合作
  • 市场限制与课题
    • 药品审批的监理要求严格
    • 与透皮药物製剂相关的限制
  • 市场机会
    • 专注于个人化医疗发展
    • 药物配方的进步

第6章 粘膜药市场:波特的五力分析

第7章 粘膜药市场评估

  • 各产品
    • 鼻子喷雾
    • 锭剂
    • 薄膜
    • 其他
  • 各给药途径
    • 口服
    • 鼻腔
    • 舌下
    • 脸颊方面
  • 各流通管道
    • 医院药局
    • 零售药局
    • 线上药局
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区

第8章 粘膜药市场:企业·产品简介

  • Teva Pharmaceutical Industries Ltd
  • Indivior PLC
  • GSK plc
  • Emergent BioSolutions Inc.
  • Bayer AG
  • AbbVie Inc.
  • Organon group of companies
  • Pfizer Inc.
  • Prestige Consumer Healthcare, Inc.
  • Merck & Co., Inc.
  • Aquestive Therapeutics, Inc.
  • Ferring
  • Novartis AG
  • Adalvo Limited
  • Sumitomo Pharma Co., Ltd.
  • ZIM LABORATORIES LIMITED
  • BioXcel Therapeutics, Inc.
  • BIAL
  • Almac Group
  • Boehringer Ingelheim International GmbH

第9章 KOL的见解

第10章 计划的方法

第11章 关于DelveInsight

第12章 免责声明·联络方式

Product Code: DISR0210

Transmucosal Drugs Market by Product (Nasal Spray, Tablet, Film, and Others), Route Of Administration (Oral, Nasal, Sublingual, Buccal, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of chronic diseases and arthritis and increasing R&D activities and collaborations among key players

The transmucosal drugs market was valued at USD 16,652.02 million in 2024, growing at a CAGR of 6.85% during the forecast period from 2025 to 2032 to reach USD 28,191.42 million by 2032. The demand for transmucosal drugs is primarily being boosted by the growing prevalence of chronic diseases such as cardiovascular disease. Rising adoption of transmucosal drugs and increasing R&D activities and collaborations among key players are some of the factors that are responsible for contributing to the positive growth of the transmucosal drugs market during the forecast period from 2025 to 2032.

Transmucosal Drugs Market Dynamics:

The growing prevalence of chronic disease is expected to drive the market growth. According to data provided by the Government of the United Kingdom in March 2024, stated that there were just over 1,862,500 individuals were diagnosed with coronary heart disease (CHD) in the financial year ending 2023 in England. Sublingual tablets are designed to be placed below the tongue, where they rapidly dissolve and are absorbed directly into the bloodstream. This efficient drug absorption facilitates rapid relief for patients suffering from angina and coronary heart disease. Medications such as Nitrostat contain nitroglycerin and are used to alleviate chest pain (angina) in patients with coronary artery disease, a condition characterized by reduced blood flow to the heart. Therefore, the rising prevalence of chronic disease is expected to propel the market growth.

According to the Government of the United Kingdom in February 2024, it was reported that 21.8% of the adult population experienced depression or anxiety in the United Kingdom between 2021 and 2022. Buccal Lorazepam is used for the acute management of anxiety or seizures in specific situations. These formulations allow for rapid absorption through the mucous membranes in the mouth to provide immediate onset of action. Thus, rising neurological disorders are expected to drive the market growth.

The market growth is bolstered by the increased R&D activities by key players focused on developing advanced drugs. These players are concentrating their efforts on developing innovative medicated films that offer a rapid onset of action to enhance the efficacy of transmucosal drugs. For instance, in March 2022, Evonik launched EUDRATEC SoluFlow based on micro-particle technology for the development of oral drugs. This innovative micro-particle technology enhances the solubility of active pharmaceutical ingredients in oral drug products. Such technological innovations by key players are expected to foster market expansion.

However, stringent regulatory requirements for drug approval and limitations associated with transmucosal drug absorption, among others are some of the key constraints that may limit the growth of the transmucosal drugs market.

Transmucosal Drugs Market Segment Analysis:

Transmucosal Drugs Market by Product (Nasal Spray, Tablet, Film, and Others), Route of Administration (Oral, Nasal, Sublingual, Buccal, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the transmucosal drugs market, the tablet category is estimated to amass a significant revenue share in the transmucosal drugs market in 2024. This can be attributed to the advantages provided by buccal and sublingual tablets. The major advantage associated with this category is the rapid onset of action of active substances formulated in the buccal and sublingual tablets. They can be placed below the tongue where they absorb quickly and produce immediate effect. This tablet is developed to reduce first-pass metabolism enhance bioavailability of drugs and be convenient for patients having gastrointestinal irritation. Such advantages associated with buccal and sublingual tablets is contributing to the segment growth.

Key players in the market are developing transmucosal tablet products to strengthen their position in the market. Key players are developing drugs to increase their pharmaceutical portfolio and reinforces dedication to addressing the diverse needs of patients. For instance, in February 2024, Adalvo Limited launched Desmopressin sublingual tablets in France for the treatment of diabetes insipidus, primary nocturnal enuresis, and nocturia. Such product launches are expected to drive the market growth.

Therefore, the various advantages and applications provided by the tablet category will contribute to the growth of the segment, thereby driving the growth of the overall transmucosal drugs market during the forecast period.

North America is expected to dominate the overall transmucosal drugs market:

North America is expected to account for the highest proportion of the transmucosal drugs market in 2024, out of all regions. This is due to the rising prevalence of chronic diseases such as hypertension and neurological disease coupled with increasing R&D activities by key players are some of the key factors driving the growth of the transmucosal drugs market in North America.

As per the article published by the Centers for Disease Control and Prevention (CDC) in 2022, published that, an estimated 523 million people were suffering from cardiovascular disease across the globe. The nitroglycerin sublingual table is widely used for the acute management of angina pectoris. This drug acts by dilating coronary arteries and veins to reduce cardiac pressure and enhance blood flow to the heart to treat sudden heart pain. Therefore, the rising prevalence of heart disease is expected to propel the market growth in the region.

Major players in the market are developing innovative medicines for the treatment of neurological disorders. For instance, in April 2022, BioXcel Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) approved IGALMITM (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Such drug development by key players is expected to foster market growth in the region.

Therefore, the rising cases of chronic disease and product launches by key players are some of the key factors that are driving the growth of the transmucosal drugs market in North America.

Transmucosal Drugs Market Key Players:

Some of the key market players operating in the transmucosal drugs market include Teva Pharmaceutical Industries Ltd, Indivior PLC, GSK plc, Emergent BioSolutions Inc., Bayer AG, AbbVie Inc., Organon group of companies, Pfizer Inc., Prestige Consumer Healthcare, Inc., Merck & Co., Inc., Aquestive Therapeutics, Inc., Ferring, Novartis AG, Adalvo Limited, Sumitomo Pharma Co., Ltd., ZIM LABORATORIES LIMITED, BioXcel Therapeutics, Inc., BIAL, Almac Group, Boehringer Ingelheim International GmbH, and others.

Recent Developmental Activities in the Transmucosal Drugs Market:

  • In March 2024, BIAL, launched KYNMOBI (apomorphine hydrochloride) in Germany. KYNMOBI is the sublingual film for the intermittent treatment of OFF episodes in adult patients with Parkinson's disease.
  • In March 2024, Tonix Pharmaceuticals announced its collaboration with Almac Pharma Services for the launch and commercialization of TonmyaTM (cyclobenzaprine HCl sublingual tablets) in the U.S. Tonmya is a centrally acting opioid analgesic for the treatment of fibromyalgia.
  • In December 2022, Aquestive Therapeutics, announced the completion of phase-2 clinical trial for AQST-109. It is an epinephrine sublingual film designed to treat severe allergic reactions such as anaphylaxis.

Key Takeaways from the Transmucosal Drugs Market Report Study

  • Market size analysis for current Transmucosal Drugs Market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the Transmucosal Drugs market.
  • Various opportunities available for the other competitors in the Transmucosal Drugs Market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current Transmucosal Drugs market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Transmucosal Drugs market growth in the coming future?

Target Audience who can be benefited from this Transmucosal Drugs Market Report Study

  • Transmucosal Drugs product providers
  • Research organizations and consulting companies
  • Transmucosal Drugs related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in Transmucosal Drugs
  • Various end-users who want to know more about the Transmucosal Drugs Market and the latest technological developments in the Transmucosal Drugs Market.

Frequently Asked Questions for the Transmucosal Drugs Market:

1. What are Transmucosal Drugs?

  • Transmucosal drugs are pharmaceutical products designed for rapid absorption through mucous membranes, such as those in the oral or nasal cavities, facilitating rapid onset of action, and reducing first-pass metabolism to enhance bioavailability.

2. What is the market for Transmucosal Drugs?

  • The transmucosal drugs market was valued at USD 16,652.02 million in 2024, growing at a CAGR of 6.85% during the forecast period from 2025 to 2032 to reach USD 28,191.42 million by 2032.

3. What are the drivers for the Transmucosal Drugs market?

  • The transmucosal drugs market is slated to witness prosperity owing to factors such as the growing prevalence of chronic diseases such as cardiovascular disease. Rising adoption of transmucosal drugs and increasing R&D activities and collaborations among key players are some of the key factors resulting in appreciable revenue growth in the Transmucosal Drugs Market during the forecast period (2025 to 2032).

4. Who are the key players operating in the Transmucosal Drugs market?

  • Some of the key market players operating in the transmucosal drugs market include Teva Pharmaceutical Industries Ltd, Indivior PLC, GSK plc, Emergent BioSolutions Inc., Bayer AG, AbbVie Inc., Organon group of companies, Pfizer Inc., Prestige Consumer Healthcare, Inc., Merck & Co., Inc., Aquestive Therapeutics, Inc., Ferring, Novartis AG, Adalvo Limited, Sumitomo Pharma Co., Ltd., ZIM LABORATORIES LIMITED, BioXcel Therapeutics, Inc., BIAL, Almac Group, Boehringer Ingelheim International GmbH, and others.

5. Which region has the highest share in the Transmucosal Drugs market?

  • North America is expected to account for the highest proportion of the transmucosal drugs market in 2024, out of all regions. This is due to the rising prevalence of chronic diseases such as hypertension and neurological disease coupled with increasing R&D activities by key players are some of the key factors driving the growth of the transmucosal drugs market in North America.

Table of Contents

1. Transmucosal Drugs Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Transmucosal Drugs Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Transmucosal Drugs Market Key Factors Analysis

  • 5.1. Transmucosal Drugs Market Drivers
    • 5.1.1. The growing prevalence of chronic diseases
    • 5.1.2. Rising adoption of transmucosal drugs
    • 5.1.3. Increasing R&D activities and collaborations among key players
  • 5.2. Transmucosal Drugs Market Restraints and Challenges
    • 5.2.1. Stringent regulatory requirements for drug approval
    • 5.2.2. Limitations associated with transmucosal drug formulation
  • 5.3. Transmucosal Drugs Market Opportunity
    • 5.3.1. Focus on personalized drug development
    • 5.3.2. Advancements in drug formulations

6. Transmucosal Drugs Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Transmucosal Drugs Market Assessment

  • 7.1. By Product
    • 7.1.1. Nasal Spray
    • 7.1.2. Tablet
    • 7.1.3. Film
    • 7.1.4. Others
  • 7.2. By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Nasal
    • 7.2.3. Sublingual
    • 7.2.4. Buccal
    • 7.2.5. Others
  • 7.3. By Distribution Channel
    • 7.3.1. Hospitals Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. Online Pharmacy
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.1.2. Canada Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.1.3. Mexico Transmucosal Drugs Market Size in USD million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.2.2. Germany Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.2.3. United Kingdom Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.2.4. Italy Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.2.5. Spain Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.2.6. Rest of Europe Transmucosal Drugs Market Size in USD million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.3.2. Japan Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.3.3. India Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.3.4. Australia Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.3.5. South Korea Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Transmucosal Drugs Market Size in USD million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.4.2. Africa Transmucosal Drugs Market Size in USD million (2022-2032)
      • 7.4.4.3. South America Transmucosal Drugs Market Size In USD Million (2022-2032)

8. Transmucosal Drugs Market Company and Product Profiles

  • 8.1. Teva Pharmaceutical Industries Ltd
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Indivior PLC
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. GSK plc
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Emergent BioSolutions Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Bayer AG
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. AbbVie Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Organon group of companies
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Pfizer Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Prestige Consumer Healthcare, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Merck & Co., Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Aquestive Therapeutics, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Ferring
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Novartis AG
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Adalvo Limited
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Sumitomo Pharma Co., Ltd.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. ZIM LABORATORIES LIMITED
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. BioXcel Therapeutics, Inc.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. BIAL
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Almac Group
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Boehringer Ingelheim International GmbH
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Transmucosal Drugs Market in Global (2022-2032)
  • Table 3: Transmucosal Drugs Market in Global by Product (2022-2032)
  • Table 4: Transmucosal Drugs Market in Global by Route of Administration (2022-2032)
  • Table 5: Transmucosal Drugs Market in Global by Distribution Channel (2022-2032)
  • Table 6: Transmucosal Drugs Market in Global by Geography (2022-2032)
  • Table 7: Transmucosal Drugs Market in North America (2022-2032)
  • Table 8: Transmucosal Drugs Market in the United States (2022-2032)
  • Table 9: Transmucosal Drugs Market in Canada (2022-2032)
  • Table 10: Transmucosal Drugs Market in Mexico (2022-2032)
  • Table 11: Transmucosal Drugs Market in Europe (2022-2032)
  • Table 12: Transmucosal Drugs Market in France (2022-2032)
  • Table 13: Transmucosal Drugs Market in Germany (2022-2032)
  • Table 14: Transmucosal Drugs Market in United Kingdom (2022-2032)
  • Table 15: Transmucosal Drugs Market in Italy (2022-2032)
  • Table 16: Transmucosal Drugs Market in Spain (2022-2032)
  • Table 17: Transmucosal Drugs Market in Rest of Europe (2022-2032)
  • Table 18: Transmucosal Drugs Market in Asia-Pacific (2022-2032)
  • Table 19: Transmucosal Drugs Market in China (2022-2032)
  • Table 20: Transmucosal Drugs Market in Japan (2022-2032)
  • Table 21: Transmucosal Drugs Market in India (2022-2032)
  • Table 22: Transmucosal Drugs Market in Australia (2022-2032)
  • Table 23: Transmucosal Drugs Market in South Korea (2022-2032)
  • Table 24: Transmucosal Drugs Market in Rest of Asia-Pacific (2022-2032)
  • Table 25: Transmucosal Drugs Market in Rest of the World (2022-2032)
  • Table 26: Transmucosal Drugs Market in the Middle East (2022-2032)
  • Table 27: Transmucosal Drugs Market in Africa (2022-2032)
  • Table 28: Transmucosal Drugs Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Transmucosal Drugs Market in Global (2022-2032)
  • Figure 3: Transmucosal Drugs Market in Global by Product (2022-2032)
  • Figure 4: Transmucosal Drugs Market in Global by Route of Administration (2022-2032)
  • Figure 5: Transmucosal Drugs Market in Global by Distribution Channel (2022-2032)
  • Figure 6: Transmucosal Drugs Market in Global by Geography (2022-2032)
  • Figure 7: Transmucosal Drugs Market in North America (2022-2032)
  • Figure 8: Transmucosal Drugs Market in the United States (2022-2032)
  • Figure 9: Transmucosal Drugs Market in Canada (2022-2032)
  • Figure 10: Transmucosal Drugs Market in Mexico (2022-2032)
  • Figure 11: Transmucosal Drugs Market in Europe (2022-2032)
  • Figure 12: Transmucosal Drugs Market in France (2022-2032)
  • Figure 13: Transmucosal Drugs Market in Germany (2022-2032)
  • Figure 14: Transmucosal Drugs Market in United Kingdom (2022-2032)
  • Figure 15: Transmucosal Drugs Market in Italy (2022-2032)
  • Figure 16: Transmucosal Drugs Market in Spain (2022-2032)
  • Figure 17: Transmucosal Drugs Market in Rest of Europe (2022-2032)
  • Figure 18: Transmucosal Drugs Market in Asia-Pacific (2022-2032)
  • Figure 19: Transmucosal Drugs Market in China (2022-2032)
  • Figure 20: Transmucosal Drugs Market in Japan (2022-2032)
  • Figure 21: Transmucosal Drugs Market in India (2022-2032)
  • Figure 22: Transmucosal Drugs Market in Australia (2022-2032)
  • Figure 23: Transmucosal Drugs Market in South Korea (2022-2032)
  • Figure 24: Transmucosal Drugs Market in Rest of Asia-Pacific (2022-2032)
  • Figure 25: Transmucosal Drugs Market in Rest of the World (2022-2032)
  • Figure 26: Transmucosal Drugs Market in the Middle East (2022-2032)
  • Figure 27: Transmucosal Drugs Market in Africa (2022-2032)
  • Figure 28: Transmucosal Drugs Market in South America (2022-2032)
  • Figure 29: Market Drivers
  • Figure 30: Market Barriers
  • Figure 31: Marker Opportunities
  • Figure 32: PORTER'S Five Force Analysis